Hongene Biotech is a producer of RNA building blocks – the first step for what’s possible in RNA drug-discovery and development. David Butler, Ph.D., Chief Technology Officer of Hongene, joins the Patient Empowerment Program to discuss why Hongene aims to help make RNA medicines accessible and affordable for patients everywhere, regardless of prevalence.

On this episode we discuss:

2:40 Hongene Biotech and what do they do

8:09 The early days of nucleoside building blocks and maturation of Hongene

12:00 Hongene is a strong supporter of n-Lorem. Why?

15:30 David’s origins in the chemistry field

17:38 Incremental progress that has been made in science and manufacturing

Links:

2024 Colloquium - https://www.nlorem.org/nano-rare-patient-colloquium-2024/

Make Hope Possible with a Donation - https://www.nlorem.org/donate/

Hongene - https://www.hongene.com/

On This Episode We Discuss:

• Questions we can answer and teach us about health and disease and opportunities to treat more common diseases
• What are all the functions of human genes?
• Are there gene products that have redundant functions?
• Do identical mutations cause identical phenotypes?
• n-Lorem can demonstrate that ASOs work on general types of disease challenges

The knowledge we are gaining at n-Lorem has even more value than benefiting nano-rare patients and their families. These insights will enable scientists to discover new therapeutic targets for both common and rare diseases, fundamentally changing the way we approach health and disease.

On This Episode We Discuss:

• Two most common words in medicine: Health and Disease
• The Scientific Method
• The Importance of Single Variables
• Orthogonal Thinking
• We Are at a Unique Moment in Medical History
• Genomics
• Advances in Omics
• Biological Networks and AI
• Facile Collection, Maintenance, Growth and Differentiation in the Lab
• Antisense Technology